[2-Hydroxy-2-(1-hydroxybutan-2-yloxy)ethyl] 5-[4-[3-(6-morpholin-4-yl-8-oxa-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaen-4-yl)phenoxy]carbonyloxybutylamino]-5-oxopentanoate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃吡啶类
• 英文名称: [2-Hydroxy-2-(1-hydroxybutan-2-yloxy)ethyl] 5-[4-[3-(6-morpholin-4-yl-8-oxa-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaen-4-yl)phenoxy]carbonyloxybutylamino]-5-oxopentanoate
• 英文别名: [2-hydroxy-2-(1-hydroxybutan-2-yloxy)ethyl] 5-[4-[3-(6-morpholin-4-yl-8-oxa-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaen-4-yl)phenoxy]carbonyloxybutylamino]-5-oxopentanoate
• 化学式: C₃₅H₄₃N₅O₁₁
• 分子量: 709.7
• InChiKey: PBDIPVUQLLDKCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  51
• 可旋转键数：
  21
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.49
• 拓扑面积：
  205
• 氢给体数：
  3
• 氢受体数：
  15

文献信息

• [EN] PROTEIN-POLYMER-DRUG CONJUGATES<br/>[FR] CONJUGUÉS PROTÉINE-POLYMÈRE-MÉDICAMENT
  申请人：MERSANA THERAPEUTICS INC

  公开号：WO2014093394A1

  公开（公告）日：2014-06-19

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by Lp. Each occurrence of D is independently a therapeutic agent having a molecular weight < 5 kDa. LD and Lp are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer- drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.